Hereditary Amyloidosis Support Conference

D.J. Keohane, MD Senior Director/Neuroscience Team Lead Pfizer Specialty Care



ADVANCING SCIENCE *S* IMPROVING LIVES

Regulatory Considerations for our Discussion Today

- **The pharmaceutical industry is highly regulated**
- FDA has specific rules/regulations around interactions with patients and patient organizations
- One very specific rule deals with an industry representative presenting safety or efficacy information around an agent that is still investigation in the US (ie. not approved for marketing)
 - Commentary would be seen as "pre-approval promotion"
 - FDA has recently cited two companies for such an issue
 - One based on commentary on a website
 - Another based on commentary from a clinical trial investigator
- **Therefore, my presentation today will be top-line**



ADVANCING SCIENCE 2 IMPROVING LIVES

Tafamidis Clinical Trial Update (TTR-FAP)

- Study Fx-005 completed
 - 18 month DB, PC study of safety & efficacy in 128 patients with V30M TTR-FAP
- **Study Fx-006 completed**
 - 12 month OL extension study of Fx-005 in 86 patients with V30M TTR-FAP
- **Study Fx1A-OS-001 completed**
 - Cross-sectional correlation study of the clinical outcomes measures (NIS-LL & Norfolk QOL-DN) in 51 patients with V30M TTR-FAP and 16 healthy controls
- Study Fx1A-201 completed
 - 12 month OL study of safety & efficacy in 21 patients with non-V30M TTR-FAP
- Study Fx1A-303 ongoing
 - OL study of 80 V30M patients originally enrolled in the Fx-005 study






US Regulatory Update for tafamidis

- **US NDA for tafamidis submitted to FDA in Q1 2011**
- **Pfizer received Refusal-to-File (RTF) from FDA in Q2 2011**
 - Did not provide comment as to acceptability of clinical data
 - FDA determined submission was not sufficiently complete to permit a substantive review
 - Pfizer believes additional information needed to support filing is available without further clinical studies
- Pfizer continues to work towards addressing issues in RTF and is committed to resubmission of the application this year

ADVANCING SCIENCE



Pfizer Specialty Care: A Broad In-Line Portfolio Targeting Serious Diseases





Ţ

ADVANCING SCIENCE *S* IMPROVING LIVES

Pfizer's Commitment to the Rare Disease Patient

